Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Immunity|November 23, 2021
Delayed antiretroviral therapy in HIV-infected individuals leads to irreversible depletion of skin- and mucosa-resident memory T cellsSimona Saluzzo, Ram Vinay Pandey, Laura Marie Gail, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 9, 2020
Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver diseaseBenedikt Simbrunner, Alexander Stadlmann, Philipp Schwabl, et al.
Annals of Surgery|May 15, 2019
Prognostic Factors Change Over Time After Hepatectomy for Colorectal Liver Metastases: A Multi-institutional, International Analysis of 1099 PatientsGeorgios Antonios Margonis, Stefan Buettner, Nikolaos Andreatos, et al.
Gastroenterology|June 19, 2021
Mucosal Biofilms Are an Endoscopic Feature of Irritable Bowel Syndrome and Ulcerative ColitisMaximilian Baumgartner, Michaela Lang, Hunter Holley, et al.
Anticancer Research|May 2, 2018
Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case SeriesAmar Deshwar, Georgios Antonios Margonis, Nikolaos Andreatos, et al.
JAMA Surgery|May 26, 2018
Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver CancerGeorgios Antonios Margonis, Stefan Buettner, Nikolaos Andreatos, et al.
Annals of Surgery|August 8, 2019
The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status: A Study By the International Genetic Consortium for Colorectal Liver MetastasisGeorgios Antonios Margonis, Neda Amini, Stefan Buettner, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|October 6, 2021
Mutant KRAS as a prognostic biomarker after hepatectomy for rectal cancer metastases: Does the primary disease site matter?Neda Amini, Nikolaos Andreatos, Georgios Antonios Margonis, et al.
Pageof 4